ロード中...

Molecular signatures of chronic myeloid leukemia stem cells

BCR-ABL tyrosine kinase inhibitors (TKIs) are effective in controlling Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) are unlikely to cure the disease because TKIs are unable to eradicate leukemia stem cells (LSCs) responsible for the disease relapse even after tyrosine kinase inhibiti...

詳細記述

保存先:
書誌詳細
主要な著者: Chen, Yaoyu, Li, Shaoguang
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2013
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177606/
https://ncbi.nlm.nih.gov/pubmed/24252550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-7771-1-21
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!